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Highlights 
 Metric learning reveals continuous prognostic scores of cognitive decline due to AD 
 Individualised disease trajectory modelling benefits from adding non-invasive biomarkers. 
 Interpretable and interoperable markers of progression to dementia for patient stratification  
  
         
 2 
Modelling prognostic trajectories of cognitive decline due to Alzheimer’s disease 
Joseph Giorgio
1
, Susan Landau
2
, William Jagust
2
, Peter Tino
3
, Zoe Kourtzi
1
, for the 
Alzheimer’s Disease Neuroimaging Initiative* 
1 
Department of Psychology, University of Cambridge, Cambridge, United Kingdom 
2 
Helen Wills Neuroscience Institute, University of California, Berkeley, CA USA 
3 
School of Computer Science, University of Birmingham, Birmingham, United Kingdom 
  
Running title: 
Modelling of dementia progression pathways 
Correspondence: 
Zoe Kourtzi 
Department of Psychology 
University of Cambridge 
Cambridge, UK 
Email: zk240@cam.ac.uk 
*Data used in preparation of this article were obtained from the Alzheimer’s disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators 
within the ADNI contributed to the design and implementation of ADNI and/or provided data 
but did not participate in analysis or writing of this report. A complete listing of ADNI 
investigators can be found at: 
http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
         
 3 
Abstract 
Alzheimer’s disease (AD) is characterised by a dynamic process of neurocognitive changes 
from normal cognition to mild cognitive impairment (MCI) and progression to dementia. 
However, not all individuals with MCI develop dementia. Predicting whether individuals 
with MCI will decline (i.e. progressive MCI) or remain stable (i.e. stable MCI) is impeded by 
patient heterogeneity due to comorbidities that may lead to MCI diagnosis without 
progression to AD. Despite the importance of early diagnosis of AD for prognosis and 
personalised interventions, we still lack robust tools for predicting individual progression to 
dementia. Here, we propose a novel trajectory modelling approach based on metric learning 
(Generalised Metric Learning Vector Quantization) that mines multimodal data from MCI 
patients in the Alzheimer’s disease Neuroimaging Initiative (ADNI) cohort to derive 
individualised prognostic scores of cognitive decline due to AD. We develop an integrated 
biomarker generation– using partial least squares regression– and classification methodology 
that extends beyond binary patient classification into discrete subgroups (i.e. stable vs. 
progressive MCI), determines individual profiles from baseline (i.e. cognitive or biological) 
data and predicts individual cognitive trajectories (i.e. change in memory scores from 
baseline). We demonstrate that a metric learning model trained on baseline cognitive data 
(memory, executive function, affective measurements) discriminates stable vs. progressive 
MCI individuals with high accuracy (81.4%), revealing an interaction between cognitive 
(memory, executive functions) and affective scores that may relate to MCI comorbidity (e.g. 
affective disturbance). Training the model to perform the same classification task on 
biological data (mean cortical -amyloid burden, grey matter density, APOE 4) results in 
similar prediction accuracy (81.9%). However, training the model with biological (r=-0.68) 
rather than cognitive data (r=-0.4) shows significantly better performance in predicting 
individualised rate of future cognitive decline (i.e. change in memory scores from baseline). 
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Our trajectory modelling approach reveals interpretable and interoperable markers of 
progression to AD and has strong potential to guide effective stratification of individuals 
based on prognostic disease trajectories, reducing MCI patient misclassification, that is 
critical for clinical practice and discovery of personalised interventions. 
 
Keywords: machine learning, mild cognitive impairment, Alzheimer’s disease brain imaging, 
cognition 
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Introduction 
Progression to dementia due to Alzheimer’s Disease (AD) involves multiple pathways of 
disease pathophysiology that impact cognition (Clifford R Jack et al., 2010; Jack et al., 2018, 
2013; Jagust, 2018). Individuals who develop dementia follow a trajectory from a stage of 
normal cognition to Mild Cognitive Impairment (MCI) and subsequent dementia (McKhann 
et al., 2011; Petersen et al., 2001; Sperling et al., 2011). Predicting early onset of 
neurocognitive decline due to AD has major implications for timely clinical management and 
patient outcomes. Yet, diagnosis at early stages of disease is impeded by heterogeneity in 
patient populations due to comorbidities (e.g. affective or cerebrovascular disorders) that may 
lead to MCI diagnosis without further progression to AD (Petersen, 2009). Determining 
disease trajectories for individuals diagnosed with MCI has major implications for prognosis 
and personalised interventions. 
Recent advances in machine learning allow us to develop predictive models of 
neurodegenerative disease by mining multimodal datasets that include measurements of 
cognition and neuropathology from large patient cohorts (Woo et al., 2017). In line with the 
2011 NIA-AA diagnostic framework for mild cognitive impairment or dementia stages in AD 
(Albert et al., 2011; McKhann et al., 2011), most machine learning models in AD have 
focused on binary classifications. For example, machine learning models have been shown to 
predict with high accuracy whether individuals diagnosed with MCI will decline (i.e. 
progressive MCI; pMCI) or remain stable (i.e. stable MCI; sMCI) (Rathore et al., 2017). 
Fewer models have achieved prediction of individual variability in disease progression (Tang 
et al., 2015; Woo et al., 2017) focusing primarily on probabilistic estimates of time to 
conversion to AD (Alsaedi et al., 2018; Casanova et al., 2013; Desikan et al., 2010; Clifford 
R. Jack et al., 2010; Liu et al., 2017; Michaud et al., 2017; Oulhaj et al., 2009; Young et al., 
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2014), with some models estimating exact time to conversion (Dukart et al., 2015; Thung et 
al., 2018; Vogel et al., 2018).  
Despite the high prediction accuracies achieved by machine learning algorithms, binary 
classification approaches are poorly constrained, as they are based on clinical labels rather 
than capturing information in longitudinal patient trajectories. As a result, individual patients 
at the class boundary that differ only slightly in their profile may be misclassified. Further, 
the validity and statistical power (Li et al., 2019) of these approaches is limited by the 
frequency of clinical follow-ups (i.e. the point of conversion may occur between clinical 
assessments) and inter-rater reliability (i.e. clinicians may differ in their assessment). 
Extending machine learning modelling to predict measures determined by diagnostic 
labelling (i.e. time to conversion) suffers from the same limitations, introducing bias and 
limiting the interpretability and interoperability of machine learning algorithms (Janssen et 
al., 2018). Thus, novel modelling approaches that predict individualised trajectories of 
cognitive decline based on continuous measures need to be developed to enhance clinical 
validity and guide effective clinical interventions and drug discovery trials. 
 Here, we develop and implement a trajectory modelling approach that extends beyond binary 
classification. We use machine learning (metric learning) algorithms to stratify patients at 
early stages of impairment (i.e. MCI) based on baseline cognitive or biological data and 
determine individual prognostic trajectories based on continuous measures of cognitive 
decline (i.e. change in memory scores over time). Our trajectory modelling approach allows 
us to extract continuous information about progression to AD, in line with the current 2018 
NIA-AA research framework that has transitioned to defining AD as a continuum (Jack et al., 
2018). 
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In particular, we used large-scale data from the Alzheimer’s disease Neuroimaging Initiative 
(ADNI) database. Cognitive data comprise composite scores across tasks; that is, summative 
measures of memory (i.e., ADNI- Mem (Crane et al., 2012)), executive function (i.e., ADNI 
–EF (Gibbons et al., 2012)), and depression (Yesavage, 1988). Similar composite measures 
have been shown to be effective for diagnosing cognitive dysfunction (Ayutyanont et al., 
2014; Donohue et al., 2014; Jutten et al., 2018, 2017; Langbaum et al., 2014). In addition, we 
used well-studied biomarkers of AD (Jagust, 2018; Resnick and Sojkova, 2011); that is, grey 
matter density derived from structural MRI scans, -amyloid burden from PET scans and 
APOE 4 status.  
We adopted a metric learning framework (Generalised Metric Learning Vector Quantization, 
GMLVQ) and extended our approach beyond binary classification (i.e. sMCI vs. pMCI) to 
modelling of continuous measurements (i.e. change in ADNI-Mem scores). In particular, we 
first tested a low-parameter, interpretable model on a binary classification task (sMCI vs. 
pMCI) and interrogated the key cognitive predictors that separate sMCI vs. pMCI 
individuals. This modelling revealed ADNI-Mem as the most discriminative cognitive feature 
for classifying sMCI vs pMCI, in line with previous work showing that ADNI-Mem captures 
memory performance in amnestic MCI populations (Crane et al., 2012). We then developed a 
novel feature selection and construction method based on partial least squares regression 
(PLSr) to generate an interpretable and interoperable disease-specific biomarker (i.e. grey 
matter atrophy due to AD) that predicts memory deficits as measured by ADNI-Mem, 
discriminates sMCI vs. pMCI individuals and relates to individual tau burden, as measured 
by flortaucipir PET in an independent sample. We then trained our metric learning model on 
biological data– including the PLS-derived grey-matter feature, mean cortical -amyloid 
burden, and APOE 4– and compared the classification accuracy across models trained with 
either cognitive or biological data.  
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To extend our modelling approach beyond binary classification (i.e. sMCI vs. pMCI), we 
derived a scalar projection (i.e. distance of each individual from the sMCI prototype) based 
on the metric learning model that allows us to determine a continuous metric of disease 
progression. We demonstrate that this metric relates to rate of future cognitive decline (i.e. 
change in ADNI-Mem scores following baseline), providing evidence that our methodology 
delivers a continuous prognostic score of individual cognitive decline due to AD. Further, our 
trajectory modelling approach determines predictive cognitive markers of individual 
variability in AD progression; yet, predicting disease trajectories improves when including 
non-invasively measured and interpretable biomarkers (i.e. grey matter density and/or APOE 
4).  
Methods and materials 
ADNI Participants 
Data were obtained from the Alzheimer’s disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. A major goal of ADNI has been to examine 
biomarkers including serial magnetic resonance imaging (MRI), and positron emission 
tomography (PET), with clinical and neuropsychological assessment to predict outcomes in 
mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Data samples are 
defined as: (1) Development data samples used for model formulation and within-sample 
validation, (2) independent validation data samples used for out-of-sample validation. Below 
we provide details for each data sample: 
1. Development Sample: Data from 589 individuals (baseline diagnoses: Normal =317, 
MCI=272) from ADNI-GO and ADNI-2 were used for model formulation and within-sample 
validation. For these individuals the baseline assessments (MRI and cognitive) were those 
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closest to the time of the first florbetapir (FBP) PET scan. All individuals had baseline 
cognitive measurements, 3T structural MRI, FBP-PET scan for measuring -amyloid, and 
APOE genotyping. All individuals were included in this cross sectional sample independent 
of their future diagnosis (i.e. whether following baseline an individual’s diagnosis changed 
from cognitively normal to MCI/AD). 
Development Sample I: 253 MCI individuals (of a total of 272) have at least 3 longitudinal 
cognitive testing sessions. Data from these individuals were used for model formulation and 
within-sample validation for the continuous longitudinal outcome prediction models.  
Development Sample II: 167 MCI individuals (of the 253 MCI individuals in Development 
Sample I) have 3 years of clinical diagnostic assessments. Data from these individuals were 
used as dichotomous outcomes (stable vs. progressive MCI) for longitudinal predictions.  
2. Cross-modal associations validation sample: To out-of-sample-validate the model that 
predicted cross-modality associations (e.g. predict ADNI-Mem scores from grey-matter), we 
drew an independent validation sample comprised of 446 individuals (Normal=263, 
MCI=172, AD=11) from ADNI-3. These individuals have a 3T structural MRI, and cognitive 
measures in addition to a flortaucipir (FTP) PET scan for measuring cortical tau.   
Cross-modal associations validation sample I: We selected 219 individuals from the Cross-
modal associations validation sample (Normal=122, MCI=89, AD=8), excluding individuals 
with an FTP-PET scan who were part of the Development Sample. Individuals in the Cross-
modal associations validation sample I were newly recruited into ADNI-3, that is they had 
not been enrolled in ADNI-GO or ADNI-2 prior to enrolling in ADNI-3. This independent 
sample was used to validate cross-modal associations of grey matter and ADNI-Mem scores. 
All data from the Cross-modal associations validation sample were taken from assessments 
closest in time to the FTP-PET scan.  
         
 10 
3. Longitudinal prediction validation sample: To out-of-sample-validate the model that 
generated longitudinal predictions, we drew an independent validation sample comprising 
126 MCI individuals (ADNI-GO, ADNI-2). These individuals have baseline cognitive, 3T 
structural MRI, FBP-PET measurements and APOE 4 genotyping. As for the data used for 
model formulation, baseline was defined as the assessment closest in time to an individual’s 
first FBP-PET scan acquired in ADNI. These individuals also have at least 3 longitudinal 
cognitive testing sessions that were used to validate the outcome measures for longitudinal 
predictions. See Supplementary Table S1 for sample demographics. 
 
Figure 1 
Brain Imaging data 
MRI Acquisition 
Structural MRIs were acquired at ADNI-GO, ADNI-2 and ADNI-3 sites equipped with 3 T 
MRI scanners using a 3D MP-RAGE or IR-SPGR T1-weighted sequences, as described 
online (http://adni.loni.usc.edu/methods/documents/mri-protocols). 
PET Acquisition 
PET imaging was performed at each ADNI site according to standardised protocols. The 
FBP-PET protocol entailed the injection of 10 mCi with acquisition of 20 min of emission 
data at 50-70 min post injection. The FTP-PET protocol entailed the injection of 10 mCi of 
tracer followed by acquisition of 30 min of emission data from 75-105 min post injection.  
Image Analysis: FTP (Flortaucipir PET) Tau 
FTP data were realigned, and the mean of all frames was used to coregister FTP to each 
participant’s MRI acquired closest to the time of the FTP-PET. FTP standardised uptake 
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value ratio (SUVR) images were normalised to inferior cerebellar grey matter (Baker et al., 
2017). MR images were segmented and parcellated using Freesurfer (V5.3) and regions of 
interest were used to extract cerebellar-normalised regional SUVR data. SUVR data was 
summarised for three Braak staging regions 12 (medial temporal), 34 (inferolateral temporal) 
and 56 (extra-temporal neocortical) by averaging uptake across individual Freesurfer region 
of interests (ROIs) comprising each Braak region (Maass et al., 2017).  Finally, we assigned 
individuals as tau positive for each Braak stage if their SUVR value was greater than the 90th 
percentile of amyloid-negative, cognitively normal individuals. 
Image Analysis: FBP (Florbetapir PET) Beta Amyloid 
FBP data were realigned, and the mean of all frames was used to co-register FBP data to each 
participant’s structural MRI. Cortical SUVRs were generated by averaging FBP retention in a 
standard group of ROIs (lateral and medial frontal, anterior and posterior cingulate, lateral 
parietal, and lateral temporal cortical grey matter) and dividing by the average uptake from a 
composite reference region (including the whole cerebellum, pons/brainstem, and eroded 
subcortical white matter regions) to create an index of global cortical FBP burden for each 
subject (Landau et al., 2015).  
Image Analysis Voxel Based Morphometry (VBM) 
Structural scans were segmented into grey matter, white matter and CSF (Cerebrospinal 
Fluid). The DARTEL toolbox (Ashburner, 2007) was then used to generate a study specific 
template to which all scans were normalised. Following this, individual grey matter 
segmentation volumes were normalised to MNI space without modulation. The unmodulated 
values for each voxel represent grey matter density at the voxel location. We chose to use the 
unmodulated grey matter data as it has been shown that there is a marked decrease in 
sensitivity to detecting abnormal regions within grey matter when the data is modulated 
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(Radua et al., 2014) (for analysis with modulated data, see Supplementary Figure S4b, 
Supplementary Table S2b). 
 All images were then smoothed using a 3mm3 isotropic kernel and resliced to MNI 
resolution 1.5x1.5x1.5 mm voxel size. We used a small kernel size, as topographically 
complex and relatively small cortical regions are likely to be affected in AD (i.e. structures 
within the medial temporal cortex; e.g. hippocampus, entorhinal cortex). It has been 
suggested that smoothing beyond a 3mm kernel may artificially link small but discrete 
clusters of voxels, reducing topographic sensitivity (Radua et al., 2014).  Further, our analysis 
applies a spatial decomposition across voxels. By sampling the spatial covariance structure 
across voxels, disease related non-parametric variations at the voxel level (that are mitigated 
using larger smoothing kernels in parametric statistical tests across participants) are preserved 
when using smaller kernel sizes, improving the efficacy of the analysis method.  All 
structural MRI pre-processing was performed using Statistical Parametric Mapping 12 
(http://www.fil.ion.ucl.ac.uk/spm/). 
Cognitive Scores 
We used three baseline cognitive scores as predictors for longitudinal models: a) composite 
scores of memory function (ADNI-Mem) derived from the Rey Auditory Verbal Learning, 
AD Assessment Schedule-Cognition, Mini-Mental State Examination and Logical Memory 
tests (Crane et al., 2012).  b) composite scores of executive function (ADNI-EF) derived from 
the WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category 
Fluency and Clock Drawing tests (Gibbons et al., 2012). c) the sum of all elements from the 
geriatric depression scale (GDS) (Yesavage, 1988). As individuals are excluded from ADNI 
with a GDS >5 we investigate affective disturbance at subthreshold levels of clinical 
depression. 
         
 13 
Generalised Metric Learning Vector Quantization (GMLVQ) 
We used the Generalised Metric Learning Vector Quantization (GMLVQ) framework 
(Schneider et al., 2009) to generate and test binary classification models (Supplementary 
Methods GMLVQ) that classify sMCI vs. pMCI individuals (Development Sample II). 
Individuals were characterised as sMCI if they repeatedly received an MCI diagnosis for 
more than three years of clinical observation. Individuals who progressed from MCI to AD 
within a window of 3 years of clinical observation were characterised as pMCI. Individuals 
who progressed from MCI to AD after 3 years were excluded from the Development Sample 
II.  
GMLVQ belongs to the class of classifiers referred to as Learning Vector Quantization 
(LVQ). These classifiers operate in a supervised manner to iteratively modify class-specific 
prototypes and learn boundaries between classes. For each training example, the closest 
prototype of each class is determined, these prototypes are then updated so that the prototype 
defining the same class is moved towards the training example and other prototype(s) 
representing different class(es) are moved further away. The Generalised Metric LVQ 
(GMLVQ) extends the LVQ utilising a full metric-tensor for a more robust distance measure. 
By applying the metric-tensor, specific feature scaling can occur while also accounting for 
different feature scales and pairwise task-conditional dependencies in the input space. 
Interrogating the diagonal terms allow us to determine the key univariate predictors for 
separating sMCI vs. pMCI patients. Further, interrogating the off diagonal terms of the metric 
tensor allow us to investigate the multivariate predictors that contribute to this classification 
task. 
GMLVQ Cognitive model 
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We used the (GMLVQ) framework to generate and test binary classification models that 
classify sMCI vs. pMCI individuals (Development Sample II) based on cognitive measures 
(GDS, ADNI-Mem and ADNI-EF).  
Partial Least Squares Regression with Recursive Feature Elimination (PLSr-RFE) 
We implemented Partial Least Squares Regression with Recursive Feature Elimination 
(PLSr-RFE) (Supplementary Methods PLS) to generate a grey matter density feature based 
on data from the Development sample (normal and MCI individuals). All 3T structural MRI 
scans in the Development sample were collected using a 3D MP-RAGE T1-weighted 
sequence. In particular, we used grey matter density measured by structural MRI as a 
predictor variable to determine multivariate relationships between grey matter voxels that 
best predict ADNI-Mem, as our GMLVQ modelling showed ADNI-Mem to be the most 
heavily weighted cognitive feature for the sMCI vs. pMCI classification. (Supplementary 
Methods PLS). We performed feature set construction using PLSr and feature reduction 
using recursive feature elimination. PLSr determines multivariate relationships between 
predictor variables to best describe response variables. In particular, PLSr applies a 
decomposition on a set of predictors to create orthogonal latent variables that show the 
maximum covariance with the response variables (Krishnan et al., 2011; McIntosh and 
Lobaugh, 2004). In our study, we used PLSr to generate a set of latent predictor variables 
from structural MRI data, where a) the number of features (i.e. grey matter voxels) is far 
greater than the number of observations (e.g. number of voxels >300,000, number of 
observations <1000), b) there is high degree of multi-collinearity between voxels. PLSr 
reduces redundant information and maximises the amount of variance that the latent variables 
predict in the response variable. Further, we performed recursive feature elimination by 
iteratively removing voxels that have weak predictive value. To determine the optimal 
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number of grey matter voxels to be retained, we used a 5 fold nested cross validation and an 
early stopping paradigm (Supplementary Methods, PLSr Recursive Feature Elimination).  
GMLVQ Biological model 
We followed the same methodology as for the GMLVQ Cognitive model (Development 
Sample II) to test the GMLVQ model on biological data. That is, we generated and tested 
binary classification models based on metric learning that discriminate between the same 
sMCI vs. pMCI individuals based on biological data (PLS derived grey matter score, β-
amyloid and APOE 4) (Supplementary Methods GMLVQ, Figure S1). Note that this 
sample includes 3 pMCI individuals who are β-amyloid negative (i.e. SUVR<1.11) at 
baseline. We did not restrict our measure of β-amyloid to a binary value but rather used 
continuous SUVR values to avoid model bias near the ADNI threshold of amyloid positivity.  
GMLVQ – Scalar Projection 
We next generated a continuous prediction using either baseline cognitive data (GDS, ADNI-
Mem, ADNI-EF) or baseline biological data (PLS Derived Grey matter score, β-amyloid, 
APOE 4) for MCI individuals (Development sample I). The GMLVQ- Scalar Projection 
method extends the GMLVQ framework to extract specific distance information from the 
sample vector    and the learnt prototypes                     . Specifically, we determine the 
distance in the learnt space (i.e. after applying the learnt metric tensor) between an individual 
with sample vector    and the learnt prototype         along the vector separating         and 
             (Supplementary Methods GMLVQ – Scalar Projection, Figure S2). 
A value of 1 indicates that a sample vector is incident to the pMCI prototype whereas a value 
of 0 indicates that a sample vector is incident to the sMCI prototype, and a value of 0.5 is the 
decision boundary separating the two classes within the binary classification framework. The 
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scalar projection has a large positive value for pMCI individuals and zero or negative value 
for sMCI individuals (Supplementary Figure S3). 
Relating the scalar projection to individual rates of future cognitive decline 
We used the GMLVQ-Scalar projection method for 253 MCI individuals (Development 
Sample I) to generate a cognitive scalar projection from baseline cognitive variables (GDS, 
ADNI-Mem, ADNI-EF), and a biological scalar projection from baseline biological variables 
(PLS Derived Grey matter score, β-amyloid, APOE 4). To test whether individual scalar 
projections relate to individual rates of future cognitive decline, we correlated (Pearson’s 
correlation) the scalar projection (generated using baseline predictors) with the rate of future 
change in ADNI-Mem scores. We computed the rate of future cognitive change by fitting a 
linear model to the ADNI-Mem scores across multiple measurements (Development Sample 
I: mean=5.7, std=1 time points; mean=4, std=1.7 years, Longitudinal prediction validation 
sample: mean=5, std=1.7 time points; mean=4.4, std=1.5 years). The slope of the linear 
model represents the rate of change in ADNI-Mem score. Individual scores higher than 2 
standard deviations from the sMCI mean score or less than 2 standard deviations from the 
pMCI mean score were determined as outliers and excluded from further analysis.  
Statistical Validation 
Within-sample validation  
To test within-sample generalisability for the GMLVQ (Development Sample II) and PLSr-
RFE (Development Sample) models we use k-fold cross validation. Within each cross fold 
we select hyper-parameters using nested cross-validation. To assess model generalisation 
performance, we averaged metrics (GMLVQ: Accuracy, Macro Averaged Error (MAE), True 
Positive (TP), True Negative (TN); PLSr-RFE: Variance Explained) from the test set across 
         
 17 
all cross folds. Within-sample generalisation for the GMLVQ-scalar projection framework 
(Development Sample I) was assessed using random resampling (1000 resamplings). We 
assessed within-sample generalisation based on the median of the correlation coefficients 
generated from the test sets across resampling using 95% confidence intervals.  
Out-of-Sample validation:  
We test the out-of-sample association of the PLS derived grey matter feature (represented by 
the voxel weight matrix) with memory (Cross-modal associations validation sample I) and 
cortical tau (Cross-modal associations validation sample) from the 3 selected Braak regions. 
Finally, we test the out-of-sample generalisability of the GMLVQ-Scalar Projection in 
predicting individual rates of future cognitive decline (Longitudinal prediction validation 
sample). To ensure that our PLS-grey matter feature is robust to different scanner sequences, 
we included 3T structural MRI scans collected using either a 3D MP-RAGE or IR-SPGR T1-
weighted sequence.  
Comparing Correlations between samples: 
To test if the relationship between the GMLVQ-Scalar Projection and rate of future cognitive 
decline is significantly different between Development sample II and the Longitudinal 
prediction validation samples we used Fisher’s r to Z transformation. To compare if the 
relationship of the GMLVQ-Scalar Projection and rate of future cognitive decline is 
significantly different between models using biological or cognitive data we generate a 
Steiger Z statistic (Steiger, 1980). See Supplementary Methods Cross Validation 
Framework for a compressive description of validation methodologies.  
 
Results 
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Cognitive Classification Models for predicting sMCI vs pMCI 
We tested whether a classification model that is based on the Generalised Metric Learning 
Vector Quantization (GMLVQ) framework and trained and tested on baseline cognitive data 
predicts progression from MCI to AD. In particular, we trained and tested both a linear and 
non-linear classifier to discriminate between sMCI and pMCI using cognitive data (Geriatric 
Depression Scale (GDS), ADNI Memory (ADNI-Mem) and ADNI Executive Function 
(ADNI-EF) from a sample of 167 MCI individuals (Development Sample II). We tuned the 
model with 2 hyper-parameters using nested cross validation and assessed its performance 
using 10-fold cross validation. The model successfully classified stable (sMCI; n=113) vs. 
progressive (pMCI; n=54) individuals [Accuracy: 81.4%, MAE: 17.6%, TP: 84.9%, TN 
79.8%]. We obtained identical performance by increasing model complexity to a non-linear 
classifier by increasing the number of prototypes per class to two [Accuracy:81.4%, 
MAE:17.6%, TP:84.9%, TN 79.8%], and therefore selected the linear model for further 
analysis. Interrogating the average metric tensor (Figure 2, Supplementary Methods 
GMLVQ, Figure S1) showed that the most predictive feature was ADNI-Mem (mean:0.55, 
std:+-0.12), while ADNI-EF (mean:0.35, std:+-0.09) and GDS (mean:0.1, std:+-0.05) had 
moderate and minor contributions to the classification task, respectively. These results 
suggest that the baseline ADNI-Mem score is the most discriminative cognitive feature for 
classifying sMCI vs. pMCI, as indicated by the diagonal terms in the metric tensor that are 
scaled to sum to one. Further, learning a metric in the input space of the classifier enables us 
to extend beyond the weighting of individual input features (such as ADNI-Mem score) and 
study the higher-order interplay between pairs of features with respect to the classification 
task.  Interrogating the off diagonal terms of the metric tensor indicates that the interaction of 
GDS with ADNI-Mem or ADNI-EF is important for classifying sMCI vs. pMCI individuals. 
The positive off-diagonal terms indicate a positive interaction between the ADNI-Mem and 
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ADNI-EF scores that group individuals from the same class. In contrast, the negative off 
diagonal terms indicate that the GDS score has a negative interaction with the ADNI-Mem 
and ADNI-EF scores and separate individuals into different classes. For example, individuals 
with similar baseline ADNI-Mem and ADNI-EF scores may be classified in different groups 
depending on their baseline GDS score, with higher scores likely reflecting affective 
disturbance and MCI comorbidity. 
Figure 2 
Composite grey matter score for predicting cross-modality associations 
We next determined the spatial distribution and weight of grey matter voxels that are 
associated with memory loss in AD. We used PLSr-RFE on data from cognitively normal and 
MCI individuals (Development Sample), to derive latent features based on whole-brain grey 
matter that predict baseline ADNI-Mem, as this was shown to be the most discriminative 
cognitive feature for classifying sMCI vs. pMCI individuals. We determined the optimal 
number of grey matter voxels and PLS dimensions to retain, using nested cross validation 
within each of 5 cross folds. We observed that the predictive voxels aggregated within the 
medial temporal cortex (Figure 3a, Supplementary Table S3) and that a single PLS 
dimension explained comparable variance in the ADNI Mem score in both training [r
2
(587) = 
0.1855, P < 0.0001] and test [r
2
(587) = 0.1756, P < 0.0001] sets (Supplementary Figure 
S4a, Supplementary Table S2a). No other PLS components were retained following cross 
validation.  
Next, we derived a PLS derived grey matter score for a validation sample that did not include 
individuals that were used in the model development (Cross-modal associations validation 
sample I). This value represents the weighted linear sum of grey matter voxels that best 
described the ADNI-Mem score in the Development sample. We showed that this score 
         
 20 
accounts significantly for variance in ADNI-Mem for the Cross-modal associations validation 
sample I (n= 219) that was not previously used in the PLSr-RFE feature generation ([r
2
(217) 
= 0.33, P < 0.0001]). This relationship remained significant when we controlled for (Age; 
r
2
(216) = 16%, P<0.0001, Gender; r
2
(216) = 24% P<0.0001, or Education; r
2
(216) =37% 
P<0.0001). It is likely that the higher variance explained by the PLS derived grey matter 
score for the validation sample I relative to the development sample is due to the significantly 
higher degree of atrophy (lower PLS grey matter score) in the validation sample I (Wilcoxon 
Signed Rank; z=-3.42, p<0.0001). That is, a greater amount of variance in ADNI-Mem is 
likely explained by the greater amount of AD related atrophy in the validation sample. 
Further, we observed significant differences (independent sample t-tests) in the PLS derived 
grey matter score between three sub-groups (cognitively normal, sMCI and pMCI) within the 
Development sample used in the PLSr-RFE analysis. In particular, the cognitively normal 
group showed significantly higher scores than the pMCI group (t(170)=9.13, P<0.0001, 
Cohens D =1.5) and the sMCI showed significantly higher score than pMCI group 
(t(165)=5.7, P<0.0001, Cohens D =0.94). However, when comparing cognitively normal vs. 
sMCI individuals we observed only a small effect [t(230)=3.7, P=0.00072 (FWE Corrected), 
Cohens D =0.48] (Figure 3b). Taken together these results suggest that the PLS derived grey 
matter score captures variance that relates to memory dysfunction (i.e. poor ADNI-Mem 
scores) due to AD. 
We next compared the variance explained in ADNI-Mem by the PLS derived grey matter 
score to the variance explained by the average grey matter density in medial temporal regions 
(i.e. amygdala, hippocampus) known to be related to ADNI-Mem (Nho et al., 2012). For each 
test set within the nested cross-validation framework, we extracted mean grey matter density 
from regions in the amygdala and hippocampus, as defined using the Brainnetome atlas (Fan 
et al., 2016). We then compared the variance explained in ADNI-Mem for these a-priori 
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selected regions with the variance explained by the PLS derived grey matter feature. We 
observed that the PLS derived grey matter score explained significantly more variance in the 
ADNI-Mem score than the mean grey matter density from a-priori selected regions in the 
medial temporal cortex (t(24)=5.6, Cohens D=1.12, P<0.0001) (Supplementary Table S4). 
This finding suggests that the multivariate relationship between grey matter voxels captured 
by the PLS accounts for higher variability in individual ADNI-Mem scores than the average 
grey matter density in brain regions defined by coarser parcellations.  
 
Figure 3 
Finally, we tested whether the PLS derived grey matter score differs across individuals that 
vary in cortical tau pathology, as measured by FTP-PET (Table 1). Comparing individuals 
from an independent sample (Cross-modal associations validation sample) with tau positive 
vs. tau negative scores (independent samples t-test) showed the strongest effect within Braak 
stage 12 [t(444)=9.6 , P<0.0001 Cohens D =1.9]. Further, the PLS derived grey matter score 
correlated (Pearson’s correlation) significantly with cortical tau burden across all individuals, 
with the strongest effect for Braak stage 12 [r
2
(444) = 0.32, P< 0.0001]. These results suggest 
that the PLS derived grey matter score relates to both memory deficits and tau deposition 
associated with AD. These results are consistent with previous studies showing a strong 
relationship between memory, medial temporal lobe atrophy, and regional (or Braak 12 stage) 
deposition of tau (Cho et al., 2016; Harrison et al., 2019; Johnson et al., 2016; Knopman et 
al., 2019; Schöll et al., 2016). 
Table 1 
Comparing the Performance of Biological vs. Cognitive Models 
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We tested whether a classification model trained and tested on baseline biological data 
discriminates sMCI vs. pMCI. We developed a biological classification model of similar 
complexity to the cognitive model (i.e. linear classifier (1 prototype per class), 3 features, 2 
hyper parameters) based on the same data sample (Development Sample II, n=167) using as 
predictors: PLS derived grey matter score, β-amyloid burden (measured by FBP-PET) and 
APOE 4 status (positive: presence of 1 or 2 APOE4 alleles, negative: no APOE4 alleles). The 
model successfully discriminated between sMCI vs. pMCI individuals [Accuracy: 81.9%, 
MAE: 18.3%, True Positive: 81.1%, True Negative 82.3%]. We observed comparable 
classification performance when we increased the complexity of the biological model to a 
non-linear classifier (2 prototypes per class) [Accuracy: 80.7%, MAE: 19.2%, True Positive: 
81.1%, True Negative: 80.5%]. The metric tensor of the model (Figure 4) indicates that the 
feature with the highest predictive value is baseline β-amyloid burden (mean:0.48, std:+-
0.16), with similar contributions from baseline PLS derived grey matter (mean:0.28, std: +- 
0.14) and APOE4 status (mean:0.24, std: +-0.10). Further, interrogating the off diagonal 
terms of the metric tensor indicated a positive interaction between baseline β-amyloid burden 
and APOE 4 status; that is baseline β-amyloid burden and APOE 4 status groups individuals 
from the same class. In contrast, we observed a negative interaction between baseline β-
amyloid burden and the baseline PLS derived grey matter score; that is, the combination of 
these features separates sMCI from pMCI individuals. For example, individuals with high 
baseline β-amyloid burden and low baseline PLS derived grey matter score (i.e. low grey 
matter density in medial temporal areas) are grouped in separate classes (sMCI vs. pMCI) 
from individuals with high baseline PLS derived grey matter score (i.e. high grey matter 
density) and low baseline β-amyloid burden. Finally, we observed no significant differences 
(t-tests across cross folds) in classification performance between the cognitive and biological 
models (Accuracy: [t(9)=-0.13, P=0.90], MAE: [t(9)=0.17, P=0.87], True Positive: 
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[t(9)=0.54, P=0.60], True Negative: [t(9)=-0.32, P=0.75]), suggesting that baseline cognitive 
and biological features contribute similarly to the binary classification of sMCI vs. pMCI 
individuals.  
Figure 4 
Trajectory modelling: Predicting Individual Variability in the Rate of Future Cognitive 
Decline  
Our analyses so far have focused on binary classifications (i.e. sMCI vs. pMCI). However, 
this approach is limited, as it assumes distinct patient classes and does not capture dynamic 
changes in disease progression over time. To extend beyond this binary framework, we 
developed a trajectory modelling approach by deriving a continuous metric based on a 
GMLVQ-scalar projection (i.e. distance of each MCI patient from the sMCI prototype) and 
using only baseline data. We then confirmed that this projection relates to individual 
variability in the rate of future cognitive decline. In particular, we defined the rate of future 
cognitive decline as the rate of change in the ADNI-Mem scores across measurements 
following baseline, where baseline is defined as the date of the FBP-PET scan used as a 
predictor for deriving the GMLVQ-scalar projection. We focussed on change in memory 
performance as measured by ADNI-Mem, as a) memory decline has been shown to occur 
prior to decline in other cognitive domains in sporadic AD, b) our metric leaning model 
showed that ADNI-Mem was the most discriminative cognitive feature for the sMCI vs. 
pMCI classification compared to the other cognitive variables tested (GDS, ADNI-EF).  We 
then tested whether this prognostic metric of future cognitive decline differs for cognitive vs. 
biological models. For the same sample used in the binary classifications (Development 
Sample II) we observed that scalar projections derived from either the cognitive or the 
biological model account significantly for variance in the rate of future memory decline 
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(Figure 5) (i.e. Cognitive: [r(165) = -0.41 (95% CI: [-0.51 -0.32]), P < 0.0001], Biological: 
[r(165) = -0.55 (95% CI: [-0.62 -0.47]), P < 0.0001]).  Further analyses showed that our 
trajectory modelling approach can be extended to predict data with less than 3 years of 
clinical diagnosis (Supplementary Figure S5) and future rate of cognitive decline as 
measured by standard clinical scales (i.e. MMSE; Supplementary Figure S6), providing 
evidence for the clinical relevance of our approach.  
Figure 5 
Further, we validated the relationship of the GMLVQ-scalar projection with cognitive decline 
for individuals with MCI against a new independent validation data sample (Longitudinal 
prediction validation sample). To calculate the scalar projections, we chose the metric tensor 
and prototype positions from the cognitive or biological models with the median test 
performance across resampling using the Development Sample II. To generate a baseline 
PLS derived grey matter score for the Longitudinal prediction validation sample, we 
multiplied the voxel weights matrix determined by PLSr-RFE on the Development sample 
(Figure 3a) with grey matter density from baseline structural scans for the longitudinal 
prediction validation sample (i.e. data not used for the PLSr-RFE feature generation). We 
observed a significant correlation of the scalar projection with the rate of future ADNI-Mem 
change for cognitive data [r(124) = -0.4, (95% CI: [-0.55 -0.25]), P < 0.0001]. This 
relationship remained significant when we controlled for: Age; [r(123) = -0.32, (95% CI: [-
0.47 -0.14]), P= 0.0003], Gender; [r(123) = -0.4, (95% CI: [-0.55 -0.22]), P< 0.0001], or 
Education; [r(123) = -0.4, (95% CI: [-0.54 -0.23]), P< 0.0001]). Further, we observed a 
significant correlation of the scalar projection with the rate of future ADNI-Mem change for 
biological data [r(124) = -0.68, (95% CI: [-0.76 -0.58]), P < 0.0001] (Figure 6). This 
relationship remained significant when we controlled for: Age; [r(123) = -0.57, (95% CI: [-
0.67 -0.46]), P< 0.0001], Gender; [r(123) = -0.63, (95% CI: [-0.71 -0.53]), P< 0.0001], 
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Education; [r(123) = -0.63, (95% CI: [-0.73 -0.53]), P< 0.0001]. This relationship was not 
significantly different between Development Sample I vs. Longitudinal prediction validation 
samples (Fisher’s r to Z, Cognitive model: [Z=-0.1, P=0.92], Biological model: [Z=-1.76, 
P=0.08]). Further, correlations between the scalar projection and the rate of future memory 
decline were significantly stronger for biological compared to cognitive models (Steiger’s Z, 
[Z=-3.86, P<0.0001]). This difference between models remained significant when we 
controlled for Age; (Steiger’s Z, [Z=-3.33, P=0.0004]), Gender; (Steiger’s Z, [Z=-3.57, 
P=0.0002]), or Education; (Steiger’s Z, [Z=-3.57, P=0.0002]). Taken together these findings 
suggest that the biological model explains significantly larger variance in the rate of future 
memory decline than the cognitive model.  
Figure 6 
Finally, we tested whether our trajectory modelling approach delivers stronger predictions 
when including non-invasively measured data modalities to the basic baseline cognitive 
model. Adding the baseline PLS derived grey matter feature and APOE 4 status to the 
cognitive model showed a substantial increase in the variance in the rate of future memory 
change explained by the scalar projection (Table 2). These results suggest that predicting the 
rate of future cognitive decline is enhanced by adding non-invasively measured baseline 
biological features to baseline cognitive data.  
Discussion 
Despite the importance of early diagnosis of Alzheimer’s disease for clinical practice and 
treatment, we still lack robust tools for predicting individual progression to dementia. The 
multimodal longitudinal measurements across large-scale samples available in ADNI provide 
a testbed for machine learning approaches that generate predictive features and discriminate 
between patient groups (Weiner et al., 2017, 2015). Here, we propose a novel trajectory 
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modelling approach based on an integrated feature generation and classification methodology 
that predicts individual disease trajectories based on continuous measures of cognitive 
decline. Our modelling approach is in line with the current 2018 NIA-AA research 
framework that defines AD as a continuum and advances the state-of-the-art and clinical 
validity of machine learning applications to the prediction of dementia due to AD in the 
following main respects. 
First, we successfully predict whether individuals will progress from MCI to dementia due to 
AD, employing a transparent machine learning approach (i.e. prototype based classifier with 
metric learning and linear decision boundary) trained on informative and interpretable 
baseline cognitive data. We show that baseline composite scores related to memory and 
executive function (ADNI-Mem, ADNI-EF composite score) are highly predictive of disease 
progression. The high cross-validated classification performance of our model is in line with 
previous studies showing that similar neuropsychological data are predictive of MCI 
progression to dementia due to AD (Belleville et al., 2017; Chapman et al., 2011; Pereira et 
al., 2018, 2017; Silva et al., 2013; Tabert et al., 2006). Further, we demonstrate a negative 
interaction between baseline cognitive (memory, executive function) and affective scores that 
separates individuals into different classes, with higher baseline affective scores potentially 
reflecting MCI comorbidity. Previous studies have shown that moderate to severe depressive 
symptoms (i.e. GDS> 15) are predictive of MCI conversion to AD (Defrancesco et al., 2017), 
while mild depressive symptoms do not increase conversion risk (Chen et al., 2008; 
Defrancesco et al., 2017). Here, we show that the interaction between scores that are 
indicative of mild depression (i.e. GDS<10) and memory dysfunction discriminates stable 
from progressive MCI individuals. Thus, our metric learning approach on multimodal data 
(i.e. cognitive and affective measurements) may provide a means of reducing MCI patient 
misclassification due to comorbidity (e.g. affective disturbance). 
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Second, we develop a supervised feature generation method (PLSr-RFE) that allows us to 
derive predictive and interpretable biomarkers based on structural brain imaging data. We 
demonstrate that grey matter density in the medial temporal lobe predicts variability in 
memory scores (i.e. ADNI-Mem score). In particular, this grey matter score is shown to be a 
highly predictive feature for the classification of sMCI vs. pMCI individuals, consistent with 
previous studies showing that grey matter density in the medial temporal lobe (MTL) is 
associated with AD (Davatzikos et al., 2009; Hedden and Gabrieli, 2004; Mak et al., 2017; 
Matsuda, 2016; Rathore et al., 2017) and ADNI-Mem scores (Nho et al., 2012). Previous 
work using a similar PLS methodology (sparse PLS) showed a similar spatial pattern of grey 
matter voxels that are predictive of MMSE scores (Monteiro et al., 2016). Extending beyond 
this work, we generate a biomarker based on a projection (PLS-derived grey matter score) 
that is shown to explain more variance in ADNI-Mem scores than the grey matter density 
estimated from the corresponding atlas-defined MTL region. Importantly, we show that this 
PLS-derived biomarker predicts cortical tau pathology as measured by PET, providing a 
strong link between regional brain atrophy, memory decline, and tau pathology (Maass et al., 
2018). Thus, our PLSr-RFE methodology has the potential to enhance interoperability across 
cohorts that typically include grey matter measurements (i.e. structural MRI scans) but may 
vary in the inclusion of other variables (e.g. cognitive or tau measurements). Here, we 
focused on grey matter density (un-modulated data), as it has been suggested to reflect 
mesoscopic grey matter thinning (Radua et al., 2014) that is evident in AD (Jagust, 2018). 
The same PLSr-RFE methodology can be extended to a wider range of measures derived 
from structural MRI scans (e.g. variation in cortical volume, shape and texture) that have 
been shown to be predictive of AD (for reviews: (Leandrou et al., 2018; Mateos-Pérez et al., 
2018; Matsuda, 2016)). 
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Third, our trajectory modelling approach (GMLVQ-Scalar Projection) extends beyond binary 
patient classification approaches (Rathore et al., 2017) that are poorly constrained. Recent 
methodological frameworks for mining neuroimaging data (Jollans et al., 2019) and 
predicting progression to AD (Samper-González et al., 2018) have focused on binary 
classifications that are based on discrete clinical labels (i.e. stable vs. progressive MCI), as 
determined by arbitrary criteria (e.g. within a 3 year period of clinical assessment). As a 
result, these approaches are limited by risk of patient misclassification. That is, patients at the 
class boundary with different disease trajectories may be classed in the same MCI group (e.g. 
a patient who progresses to AD within 1 day from clinical assessment and a patient who 
converts in 3 years will be classified as pMCI). Similarly, patients with similar disease 
trajectories may be classified in different MCI groups (e.g. a patient who converts in 3 years 
will be classified as pMCI, while a patient who remains stable for 3 years and progresses to 
dementia 1 day after the clinical assessment will be classified as sMCI). To overcome this 
limitation and make meaningful predictions in AD, modelling approaches need to capture 
continuous information in prognostic trajectories and consider target uncertainty (i.e. the 
future clinical diagnosis) (for review (Janssen et al., 2018)). Although recent time-to-event 
models (e.g. survival analysis models predicting time to conversion) (Alsaedi et al., 2018; 
Casanova et al., 2013; Desikan et al., 2010; Clifford R. Jack et al., 2010; Landau et al., 2010; 
Liu et al., 2017; Michaud et al., 2017; Oulhaj et al., 2009; Young et al., 2014) capture 
continuous information in patient trajectories they are limited by target uncertainty; that is, 
estimating the exact time to conversion is limited by the frequency of clinical follow-ups and 
poor inter-rater reliability (i.e. diagnoses may differ across clinicians).  
Our trajectory modelling approach predicts future ADNI-Mem scores based on baseline data, 
allowing us to capture individual disease trajectories and reducing the risk of patient 
misclassification. In particular, we derive continuous prognostic scores of individual 
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cognitive decline (i.e. scalar projection) by training the model based on ‘noisy’ diagnostic 
labels (i.e. patient classes that are poorly defined e.g. sMCI vs pMCI). As our metric learning 
model has limited freedom (linear low-parameter model), separating continuous target values 
(i.e. individualised cognitive trajectories) into two broad classes (sMCI vs. pMCI) forces the 
model to extract key underlying structures in the data that distinguish between target values, 
ignoring subtle differences in target values. Further, employing separate feature generation 
(i.e. PLSr-RFE) and classification (GMLVQ scalar projection) stages allows us to interrogate 
interpretable predictive features of progression to AD and derive predictions that generalise 
to patient data from independent samples from the model development sample. This is in 
contrast to deep learning methods that require large training samples and are shown to be 
difficult to interpret and generalise (Davatzikos, 2019), raising questions about the clinical 
utility of these approaches (for review (Topol, 2019)).  
Comparing our trajectory modelling methodology to binary classifications on the same data 
(i.e. cognitive vs. biological) shows dissociable results. A binary metric learning algorithm 
shows similar performance in the binary classification of MCI subgroups (sMCI vs. pMCI) 
when trained on baseline cognitive vs. biological data. In contrast, the scalar projection 
derived from biological data explains significantly higher individual variability in the rate of 
future cognitive decline than the scalar projection derived from cognitive data. Further, we 
demonstrate that the predictive power of our trajectory modelling methodology is enhanced 
when including non-invasively measured baseline biological data in addition to baseline 
cognitive data. Although our model shows high accuracy of cognitive decline when trained 
on cognitive data, there is a substantial gain in predictive efficacy when adding baseline data 
on APOE 4 status or grey matter density (PLS derived grey mater scores).  This is consistent 
with previous studies (Dukart et al., 2015; Thung et al., 2018; Vogel et al., 2018) showing 
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enhanced prediction of time to AD conversion when including biological compared to 
neuropsychological data alone.  
Previous work on trajectory modelling has focused on discretising continuous values (i.e. 
future change in cognitive scores) into latent classes that are then used as outcome measures 
in classification models (Bhagwat et al., 2018; Hochstetler et al., 2015; Wang et al., 2019; 
Wilkosz et al., 2010). For example, previous studies (Bhagwat et al., 2018) used machine 
learning (i.e. longitudinal Siamese neural-network) to fuse baseline and follow up imaging 
and clinical scores to predict whether individuals will decline fast or slow (based on MMSE 
scores) or fast, moderate or slow (based on ADAS-cog). Further studies (Hochstetler et al., 
2015) used classification and regression trees on baseline demographic, lifestyle, cognitive 
and biological data to classify individuals in three latent classes (fast, medium or slow 
decline) with similar growth patterns of cognitive and functional changes, while others 
(Wilkosz et al., 2010) used latent class trajectory models to derive six different trajectories 
for cognitive and behavioural decline due to AD. However, the generalisability and 
interoperability of these approaches have been recently questioned (Wang et al., 2019). Our 
trajectory modelling approach differs from this previous work, as it avoids assumptions 
related to discretising continuous values. In particular, we derive a continuous metric (i.e. 
scalar projection) from a discrete classification model (i.e. metric learning) that predicts 
individual rates of future cognitive change (i.e. change in ADNI-Mem).  Finally, our 
approach is in line with previous work predicting exact changes in MMSE or ADAS-Cog 
scores (Fan et al., 2008; Zhang et al., 2012). In particular, previous studies used baseline and 
follow-up structural MRI and FDG-PET data to predict future scores on cognitive tests at 
different time intervals (Zhang et al., 2012), or structural MRI to predict the rate of change in 
MMSE scores (Fan et al., 2008). Our modelling approach differs from this previous work in 
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fusing baseline multimodal data into a single metric (i.e. scalar projection) to predict future 
rates of cognitive change (i.e. change in ADNI-Mem, or MMSE scores).  
In sum, we propose a robust methodology based on modelling multimodal data that 
determines predictive and interpretable markers of individual variability in progression to 
dementia due to AD. Although our investigations have focused on amnestic MCI, our 
methodology has the potential to be extended to predict individual disease trajectories 
specific to AD subtypes, following recent work modelling neuroimaging data (Dong et al., 
2016; Young et al., 2018). Further, previous work on preclinical populations has investigated 
the role of grey matter atrophy and cortical amyloid burden in future cognitive decline (Bilgel 
et al., 2018; Burnham et al., 2016; Dumurgier et al., 2017; Insel et al., 2015). Extending our 
trajectory modelling approach to preclinical populations using multimodal data has high 
clinical relevance, especially as clinical trials are moving towards less severely affected 
individuals who are unlikely to progress over the short time scales of clinical trials (Bilgel et 
al., 2017, 2014; Grober et al., 2008; Mormino et al., 2014). Thus, our approach has strong 
potential to deliver tools of high clinical relevance that reduce patient misclassification and 
facilitate effective stratification of individuals to prognostic or treatment pathways and 
clinical trials based on individualised rates of cognitive decline.  
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Figure 1. Modelling framework. 
a. PLSr-RFE was used to generate the PLS derived grey matter score and out-of-sample-tests 
for cross modal associations. Using the Development Sample a voxel weights matrix is 
learned and validated using k-fold cross-validation to predict ADNI-Mem. Using this voxel 
weights matrix, we generated the PLS derived grey matter score for the Cross-modal 
associations validation sample to test the cross modal association between the PLS derived 
grey matter score and cortical tau (flortaucipir, or FTP-PET). We used the Cross-modal 
Associations validation sample I to out-of-sample validate the relationship between the PLS 
derived grey matter score and ADNI-Mem. The voxel weights matrix generated is then used 
to derive the PLS derived grey matter feature for the data used in panels b and c.  b. GMLVQ 
binary classification was used to discriminate between sMCI and pMCI based on biological 
or cognitive data. Using Development sample II, GMLVQ binary classifiers were trained and 
validated using k-fold cross-validation to predict progression to dementia from MCI (sMCI 
vs pMCI). (c) GMLVQ-Scalar Projection was used to generate the cognitive and biological 
scalar projections and out-of-sample validate the relationship of the scalar projections with 
rate of future cognitive decline. Using Development Sample I, cognitive and biological scalar 
projections were generated and correlated to rate of change in future ADNI-Mem scores. This 
relationship was validated using random resampling. Further, the relationship of the scalar 
projection and rate of future cognitive decline was validated with rate of change of future 
MMSE using Development Sample I. The prototype position and metric tensor learned from 
the GMLVQ-Scalar projection using Development Sample I were then used to derive the 
cognitive and biological scalar projections for the longitudinal prediction validation sample to 
test the out-of-sample relationship between the scalar projection and rate of future cognitive 
decline.  
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Figure 2. Cognitive classification Model - Metric Tensor 
Metric tensor for the classification model (sMCI vs pMCI) generated using cognitive data 
(GDS, ADNI-Mem, ADNI-EF). The colour scale indicates the predictive value for each cell 
in the metric tensor, where diagonal terms sum to 1. The diagonal terms show strong 
contribution of the ADNI-Mem score. The positive off diagonals terms indicate a positive 
interaction between the ADNI-Mem and ADNI-EF scores. The negative off diagonals terms 
indicate the negative interaction of the GDS score with the ADNI-Mem and ANDNI-EF 
scores. See also Figure S1 for examples of GMLVQ and possible interpretations. 
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Figure 3: PLS modelling of ADNI-Mem 
a. PLS derived voxel weights matrix. Voxel weights are derived using the PLSr-RFE 
methodology. Retained voxels are overlaid on the MNI template in neurological convention 
(left is left). The colour scale represents the average z-statistic of weights per voxel across all 
cross folds. All retained voxels are red indicating positive weights. Table S2 lists the 
anatomical regions and voxel weights for the PLS voxel matrix. The x, y and z coordinates 
denote the location of the sagittal, coronal and axial slices, respectively. b. PLS derived grey 
matter scores for cognitively normal, sMCI and pMCI groups: Boxplots of the PLS 
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derived grey matter scores for cognitively normal, sMCI and pMCI groups. The centre line 
represents the median and the edges of the boxes represent the 25
th
 and 75
th
 percentiles of 
each sample. The medians of two samples are significantly different at the p<0.05 if the edge 
of the intervals around each notch do not overlap. Red points denote outliers. 
 
Figure 4: Biological Classification Model - Metric Tensor 
Metric tensor for the classification model (sMCI vs pMCI) generated using biological data 
(PLS derived grey matter score, -amyloid, APOE 4). The colour scale indicates the 
predictive value for each cell in the metric tensor, where diagonal terms sum to 1. The 
diagonal terms show strong contribution of -amyloid. The positive off diagonals terms 
indicate a positive interaction between -amyloid and APOE 4. The negative off diagonals 
terms indicate the negative interaction of the PLS derived grey matter score with both -
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amyloid and APOE 4. See also Figure S1 for examples of GMLVQ and possible 
interpretations. 
 
Figure 5: Correlating GMLVQ-Scalar projections with rate of memory change:  
Correlation of the GMLVQ-scalar projections derived from the a) cognitive model, b) 
biological model with the rate of ADNI-Mem change for Development Sample I. Red dots 
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indicate pMCI individuals, blue dots indicate sMCI individuals. The central black line is the 
regression line for the fit of the GMLVQ-scalar projection to the rate of ADNI-Mem change; 
the dashed lines represent the 95% confidence intervals for this regression line. Data used to 
train the model (n=52) were not used to test the relationship between the scalar projection and 
rates of future cognitive decline and are not shown here. 
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Figure 6: Correlating Scalar projections from Cognitive and Biological Models with 
rate of memory change: Out-of-sample Validation 
Correlation of scalar projection derived from the a) cognitive model, b) biological model with 
the rate of ADNI-Mem change for the longitudinal validation data set. Red dots indicate 
pMCI individuals, blue dots sMCI individuals. The central black line is the regression line for 
the fit of the GMLVQ-scalar projection to the rate of ADNI-Mem change; the dashed lines 
represent the 95% confidence intervals for this regression line. Outliers identified by the 
Robust Correlation toolbox (cognitive n=7, Biological n=8) are not shown for illustrative 
purposes. Note that this validation sample includes data from 3 β-amyloid negative pMCI 
individuals who had a scalar projection of less than 0.25 (i.e. very close to the sMCI 
prototype). Investigating the relationship of the scalar projection to future cognitive decline 
for these individuals showed dissociable cognitive trajectories from most pMCI individuals. 
Tables 
Table 1. PLS derived grey matter score relationship with flortaucipir PET Tau 
Braak Stage Threshold Tau Positive vs Tau Negative GM Score vs Tau 
p t Cohen d Pos/Neg r
2
 
tau Braak 12 1.95 <.0001 9.7 1.9 27/419 0.32 
tau Braak 34 1.89 <.0001 8.3 1.5 33/413 0.15 
tau Braak 56 1.93 <.0001 5.7 1.3 21/425 0.08 
Table 1: relationship of the PLS grey matter score with flortaucipir Tau measures. The table 
shows the threshold for tau positivity for each of the Braak stages, the statistical differences 
between the grey matter scores for tau positive vs. tau negative individuals, and the 
correlation of the PLS grey matter score with flortaucipir tau across all individuals. 
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Table 2: Correlating Scalar projections with rate of ADNI-Mem change 
Data Type Pearson’s r [95% C.I] 
Cross Validation 
Pearson’s r  
Out-of-Sample 
Validation 
Biological: (GM+APOE4+ -Amyloid) -0.55 [-0.66 -0.53] -0.68 [-0.76 -0.58] 
Cognitive: (GDS+ADNI-Mem+ADNI-EF) -0.41 [-0.5 -0.30] -0.4  [-0.55 -0.25]  
Cognitive+GM -0.46 [-0.52 -0.34] -0.49 [0.61 -0.35] 
Cognitive+APOE 4 -0.47 [-0.55 -0.38] -0.48 [-0.61 -0.33]  
Cognitive+GM+APOE 4 -0.5 [-0.57 -0.42] -0.53 [-0.64 -0.4]  
Table 2: correlations of scalar projections with the rate of ADNI-Mem change for models 
based on cognitive and / or biological data. Pearson’s correlation coefficients are shown for 
Development Sample (b) based on cross-validation and the independent data used for out of 
sample validation (longitudinal validation sample). 
 
         
